Dextran sulfate

Drug Profile

Dextran sulfate

Latest Information Update: 04 Feb 2017

Price : $50

At a glance

  • Originator Polydex Pharmaceuticals
  • Developer National Institutes of Health (USA); Polydex Pharmaceuticals
  • Class Anticoagulants; Antihyperlipidaemics; Glucans; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer metastases; HIV infections; Ovarian cancer

Most Recent Events

  • 03 Feb 2017 Discontinued - Clinical-Phase-Unknown for Ovarian cancer in Japan (Intraperitoneal)
  • 03 Feb 2017 Discontinued - Preclinical for Cancer metastases in Japan (Intraperitoneal)
  • 21 Jun 2004 Suspended - Clinical-Phase-Unknown for Ovarian cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top